Rizzo A.; Mollica V.; Cimadamore A.; Santoni M.; Scarpelli M.; Giunchi F.; Cheng L.; Lopez-Beltran A.; Fiorentino M.; Montironi R.; Massari F., Is There a Role for Immunotherapy in Prostate Cancer?, «CELLS», 2020, 9, pp. 2051 - 2051 [Scientific article]Open Access
Kouba E.; Lopez-Beltran A.; Montironi R.; Massari F.; Huang K.; Santoni M.; Chovanec M.; Cheng M.; Scarpelli M.; Zhang J.; Cimadamore A.; Cheng L., Liquid biopsy in the clinical management of bladder cancer: current status and future developments, «EXPERT REVIEW OF MOLECULAR DIAGNOSTICS», 2020, 20, pp. 255 - 264 [Scientific article]
Donini M.; Buti S.; Massari F.; Mollica V.; Rizzo A.; Montironi R.; Bersanelli M.; Santoni M., Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions, «EXPERT REVIEW OF ANTICANCER THERAPY», 2020, 20, pp. 491 - 501 [Scientific article]
Cimadamore A.; Massari F.; Santoni M.; Mollica V.; Di Nunno V.; Cheng L.; Lopez-Beltran A.; Scarpelli M.; Montironi R.; Moch H., Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies, «EXPERT REVIEW OF MOLECULAR DIAGNOSTICS», 2020, 20, pp. 141 - 150 [Scientific article]
Montironi R.; Cimadamore A.; Lopez-Beltran A.; Scarpelli M.; Aurilio G.; Santoni M.; Massari F.; Cheng L., Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer, «CELLS», 2020, 9, Article number: 1073 , pp. 1 - 15 [Scientific article]Open Access
Aurilio G.; Cimadamore A.; Santoni M.; Nole F.; Scarpelli M.; Massari F.; Lopez-Beltran A.; Cheng L.; Montironi R., New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?, «CELLS», 2020, 9, Article number: 1522 , pp. 1 - 14 [Scientific article]Open Access
Caffo O.; Zagonel V.; Baldessari C.; Berruti A.; Bortolus R.; Buti S.; Ceresoli G.L.; Donini M.; Ermacora P.; Fornarini G.; Fratino L.; Masini C.; Massari F.; Mosca A.; Mucciarini C.; Procopio G.; Tucci M.; Verri E.; Zucali P.; Buttigliero C., On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2, «ANNALS OF ONCOLOGY», 2020, 31, pp. 1415 - 1416 [Scientific article]
Massari F.; Mollica V.; Salvagni S.; Tognetto M.; Ardizzoni A., Oncology clinical trials in the time of COVID-19: How a pandemic can revolutionize patients' care, «FUTURE ONCOLOGY», 2020, 16, pp. 1413 - 1415 [Scientific article]Open Access
Santoni M.; Massari F.; Cheng L.; Cimadamore A.; Scarpelli M.; Montironi R.; Lopez-Beltran A., Pd-l1 inhibitors for the treatment of prostate cancer, «CURRENT DRUG TARGETS», 2020, 21, pp. 1558 - 1565 [Scientific article]
Cimadamore A.; Massari F.; Santoni M.; Lopez-Beltran A.; Cheng L.; Scarpelli M.; Montironi R.; Moch H., PD1 and PD-L1 inhibitors for the treatment of kidney cancer: The role of PD-L1 assay, «CURRENT DRUG TARGETS», 2020, 21, pp. 1664 - 1671 [Scientific article]
Lamberti, Giuseppe; Brizzi, Maria Pia; Pusceddu, Sara; Gelsomino, Fabio; Di Meglio, Giovanni; Massari, Francesco; Badalamenti, Giuseppe; Riccardi, Ferdinando; Ibrahim, Toni; Ciccarese, Chiara; Buti, Sebastiano; Carnaghi, Carlo; Prinzi, Natalie; Panzuto, Francesco; Campana, Davide, Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis, «JOURNAL OF CLINICAL MEDICINE», 2020, 9, Article number: 1351 , pp. 1 - 12 [Scientific article]Open Access
Petrylak D.P.; de Wit R.; Chi K.N.; Drakaki A.; Sternberg C.N.; Nishiyama H.; Castellano D.; Hussain S.A.; Flechon A.; Bamias A.; Yu E.Y.; van der Heijden M.S.; Matsubara N.; Alekseev B.; Necchi A.; Geczi L.; Ou Y.-C.; Coskun H.S.; Su W.-P.; Bedke J.; Gakis G.; Percent I.J.; Lee J.-L.; Tucci M.; Semenov A.; Laestadius F.; Peer A.; Tortora G.; Safina S.; Garcia del Muro X.; Rodriguez-Vida A.; Cicin I.; Harputluoglu H.; Tagawa S.T.; Vaishampayan U.; Aragon-Ching J.B.; Hamid O.; Liepa A.M.; Wijayawardana S.; Russo F.; Walgren R.A.; Zimmermann A.H.; Hozak R.R.; Bell-McGuinn K.M.; Powles T.; Wong S.-L.S.; Tan T.H.; Hovey E.J.; Clay T.D.; Wan Ng S.S.; Rutten A.; Machiels J.-P.; Dumez H.; Cheng S.Y.-S.; Ferrario C.; Sengeloev L.; Jensen N.V.; Thibault C.; Laguerre B.; Joly F.; Culine S.; Becht C.; Niegisch G.; Stockle M.; Grimm M.-O.; Schwentner C.A.; Schultze-Seemann W.; Kalofonos H.; Mavroudis D.; Papandreou C.; Karavasilis V.; Revesz J.; Rosenbaum E.; Leibowitz-Amit R.; Kejzman D.; Sarid , Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial, «THE LANCET ONCOLOGY», 2020, 21, pp. 105 - 120 [Scientific article]
Mollica V.; Rizzo A.; Massari F., Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?, «EUROPEAN UROLOGY ONCOLOGY», 2020, 3, pp. 559 - 560 [Scientific article]
Di Nunno V.; Santoni M.; Gatto L.; Mollica V.; Massari F., Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. Lancet 2018;392:2353-66: Metastatic Hormone-naïve Prostate Cancer: A Multimodal Approach for a Heterogeneous Disease, «EUROPEAN UROLOGY ONCOLOGY», 2020, 3, pp. 390 - 390 [Scientific article]
Rizzo A.; Mollica V.; Massari F., Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. Eur Urol. In press DOI: 10.1016/j.eururo.2020.04.065, «JOURNAL OF CLEANER PRODUCTION», 2020, 78, pp. 205 - 206 [Scientific article]
